This new funding opportunity will provide funds necessary to apply pharmacogenetic/pharmacoepigenetic advances to the treatment of pediatric conditions. An applicant is expected to assemble and develop the infrastructure, capabilities, research programs, and teams required to: (1) conduct translational research leading to a comprehensive description of disease phenotypes of interest; (2) understanding of genetic/genomic/epigenetic basis of variability in drug responses, effects, and toxicity in the treatment of pediatric diseases/conditions; (3) apply and implement pharmacogenomics approach to clinical trial design for ongoing and future clinical trials.
Research areas appropriate for this announcement include but are not limited to, the following:
- identification of pediatric disease-specific phenotypes
- identification of polymorphisms that affect efficacy and toxicity of drug therapy in children
- identification of epigenetic factors that affect efficacy and toxicity of therapy in children
- identification of the complex interplay between disease phenotype, developmental pharmacology, and genetic and epigenetic changes
Deadlines: standard NIH deadlines apply
Filed Under: Funding Opportunities